The Royal Marsden NHS Trust, Sutton, UK E2F transcription factors, including E2F3, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P ¼ 0.0022) and cause-specific survival (P ¼ 0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of E2F3-positive nuclei identified within their prostate cancers (up to 20, 21-40%, etc.), there is an increasingly significant association between E2F3 staining and risk of death both for overall survival (P ¼ 0.0014) and for causespecific survival (P ¼ 0.0004). Multivariate analyses select E2F3 expression as an independent factor predicting overall survival (unstratified P ¼ 0.0103, stratified P ¼ 0.0086) and cause-specific survival (unstratified P ¼ 0.0288, stratified P ¼ 0.0072). When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.
Introduction
Prostate cancer is one of the commonest cancers in man in Western societies. However, the mechanisms underlying its aetiology and pathogenesis remain poorly understood. Identification of key cancer genes underpinning the genesis of this disease remains a priority (Bostwick and Foster, 1999) .
Recently, the polycomb group protein Enhancer of Zeste Homolog gene 2 (EZH2) has been implicated in the development of human prostate cancer (Varambally et al., 2002) . Functionally, EZH2 is the catalytic subunit of the polycomb repressor complex 2, and can methylate lysines 9 and 27 on histone H3. Expression microarray studies (Varambally et al., 2002) identified EZH2 as a gene overexpressed in hormone-refractory metastatic prostate cancer and have found that patients with clinically localized prostate cancers that express EZH2 have a worse prognosis than those that do not express the protein. EZH2 protein is also elevated in invasive breast cancer compared to normal breast epithelia, and its expression is strongly associated with breast cancer aggressiveness (Kleer et al., 2003) . Consistent with the oncogenic properties of EZH2, its overexpression both in human mammary epithelial cells and in primary mouse embryo fibroblasts confers a proliferative advantage (Kleer et al., 2003; Bracken et al., 2003) . EZH2 is amplified and overexpressed in a variety of cancers, with 15% of cancers, including breast and colon cancer, showing evidence of EZH2 amplification (Bracken et al., 2003) . Knocking down expression of the EZH2 protein in PC3 invasive prostate cancer cells using RNAi technology inhibited proliferation in vitro (Varambally et al., 2002) . Bracken et al. (2003) established that expression of EZH2 is controlled by the E2F transcription factors. Following serum stimulation, EZH2 expression is dependent on the presence of E2F binding sites in the promoter of EZH2. Using a chromosomal immunoprecipitation (ChIP) assay, both E2F3 and E2F4 were shown to be bound to the EZH2 promoter.
We recently demonstrated that amplification and overexpression of E2F3 may represent a facilitating mechanism in the genesis of bladder carcinogenesis (Feber et al., 2004) . High levels of expression of E2F3 were observed in approximately one-third of transitional cell carcinomas of the bladder, with the proportion of each tumour exhibiting E2F3 overexpression increasing with tumour grade and stage. In this current study, we have used tissue microarray (TMA) technology to assess whether E2F3 is also expressed at high levels in human prostate cancer. TMAs containing 774 tissue cores representing 147 different prostate cancers were used to assess the relationship between E2F3 protein expression and clinical outcome. Hence, this study was performed to test the hypothesis that enhanced expression of E2F3 is a common permissive event in human prostate cancers, particularly in the aggressive malignancies.
Results

Construction of tissue microarrays
TMAs were constructed from TURP and prostatectomy samples that had been taken from a consecutive series of patients diagnosed with prostate cancer who attended the Royal Marsden NHS Trust from 1992. The TMA of 774 cores contained prostate cancers from 147 patients. The average time of follow-up was 2186 days. Tumour demographics and characteristics are shown in Table 1 .
E2F3 immunohistochemistry
Immunohistochemical analysis of the TMA demonstrated intense nuclei staining for E2F3 in 67% (98/147) of prostate cancers (Figure 1a-c) , with the maximum proportion of cells containing nuclear staining varying from 5 to 90%. Analysis of non-neoplastic epithelium present on the TMAs revealed that hyperplastic epithelium ( Figure 1d ) and morphologically normal epithelium ( Figure 1e ) exhibited nuclear E2F3 staining in respectively 21/124 (19.8%) and 1/43 (2.33%) of cases. All samples present on the TMA were taken from patients who were diagnosed with prostate cancer. It was therefore possible that the presence of nuclear E2F3 staining in a single case of morphologically normal prostate tissue indicates that these cells, although retaining a normal morphology, contain early changes associated with the development of either prostate cancer or epithelial hyperplasia. Accordingly, we were interested in assessing E2F3 staining patterns in prostates from patients who had not been diagnosed with prostate cancer. In these analyses, we failed to detect nuclear E2F3 staining in seven prostates taken from men undergoing primary cystoprostatectomy for invasive transitional cell carcinoma of the urinary bladder, even though the area of the specimen examined for each sample was considerably greater than that scored in TMA studies. These observations are consistent with the view that increased overexpression of E2F3 is associated with prostate cancer development.
Because of the wide variation in the percentage of nuclei exhibiting staining, the data were stratified into six bands: negative, up to 20, 21-40, 41-60, 61-80 and 81-100%. The distributions of staining for prostate cancer, hyperplastic epithelium and morphologically normal epithelium are presented in Figure 2 . These analyses show that high levels of nuclear E2F3 staining (21-100%) are mainly restricted (52/59) to prostate cancer specimens.
In some cases, E2F3 was observed predominantly in the cytoplasm (Figure 1f ). This pattern, referred to as Type II staining, was not observed in prostate cancer and was restricted entirely to morphologically normal epithelium (3/43) and epithelia hyperplasia (15/124).
Correlation with clinical behaviour
Relationships between the presence or absence of nuclear E2F3 in prostate cancer and other clinicopathological parameters were assessed. There was a significant association with Gleason score (P ¼ 0.016), but no association with age (P ¼ 0.327), M stage (P ¼ 0.574) or AJCC stage (P ¼ 0.613). Figure 3 shows overall survival and cause-specific survival according to E2F3 status. For cause-specific survival, only deaths from prostate cancer were scored. These curves demonstrated a significantly increased hazard rate of patients whose cancers exhibited E2F3 expression for both overall Multivariate analysis was conducted to test the independent prognostic role of significant variables. When the variables were taken into account in a stepwise analysis, the model selected E2F3 expression as an independent factor for predicting both overall survival (P ¼ 0.0103) and cause-specific survival (P ¼ 0.0288), with respective hazard ratios for E2F3-positive tumours of 1.9290 and 1.8423. Other independent variables selected were Gleason score (P ¼ 0.0042, P ¼ 0.0009) and tumour stage (for values see Tables 2 and 3 ). No Figure 4 shows overall and cause-specific survival following stratification of patients according to the maximum percentage of E2F3-positive nuclei observed in their prostate cancer. These analyses demonstrated a significant association between the percentage of nuclear staining for E2F3 and risk of death for both overall (logrank test, df ¼ 5, P ¼ 0.0014) and cause-specific (logrank test, df ¼ 5, P ¼ 0.004) survival, observations that were confirmed in univariate Cox regression analyses (Po0.0001, Po0.0001). Multivariate analyses using stratification of E2F3 staining again identified E2F3 (P ¼ 0.0086, P ¼ 0.0072), Gleason score (P ¼ 0.0042, P ¼ 0.0090) and AJCC tumour stage (Tables 2 and 3) as independent variables.
Discussion
Immunohistochemical analysis of E2F3 has identified high nuclear expression of the E2F3 protein in 67% (98/ 145) of human prostate cancers compared to 2.3% (1/ 43) of morphologically normal prostatic epithelia in tissue specimens from men with prostate cancer. No E2F3 staining was detected in prostates taken from men who had not been diagnosed with prostate cancer. These observations are consistent with the view that upregulation of E2F3 is associated with prostate cancer development. Multivariate analysis of E2F3 immunohistochemical data in prostate cancers established that the presence of high levels of nuclear E2F3 protein is an independent marker of poor patient survival. Furthermore, the prognostic power of this marker was increased when the patients were stratified according to the maximum percentage of nuclear staining found for each cancer.
Transcription factor E2F3 has a central role in linking cell cycle proteins, such as cyclins, CDKs and pRB, to the expression of a variety of genes involved in cellular proliferation. In other studies, micorarray technology has been used to identify large sets of genes modulated by E2F3 (Muller et al., 2001; Huang et al., 2003) . The identified genes have roles in a variety of cellular processes that are altered during cell transformation (i.e., apoptosis, cell cycle transition, DNA synthesis, transcription and signal transduction) and include genes such as EZH2, Ki-67, BCL-2, follistatin, TGF-a and cMET whose enhanced expression has previously been associated with prostate cancer development, proliferation and clinical outcome (Bostwick and Foster, 1999; Varambally et al., 2002) . Indeed it is possible that E2F3 overexpression controls proliferation and hence tumour aggressiveness in human prostate cancer. Consistent with this view, in bladder cancer it has been shown that amplification of 6p22 sequences that include E2F3 is correlated with higher cancer cell proliferation rates (Tomovska et al., 2001) . E2F3 protein has recently been shown to bind to the TFE3 E-box transcription factor, an interaction that is believed to contribute to the specificity of E2F3 function (Giangrande et al., 2003) . This interaction is of interest because we have previously demonstrated that TFE3 is also involved in cancer development since the entire TFE3 protein becomes fused to the N-terminal domain of the pre-mRNA splicing proteins PRCC, PSF or NonO in human papillary renal cell cancer (Sidhar et al., 1996; Clark et al., 1997; Skalsky et al., 2001) .
When considered together with the data presented here, several lines of evidence support the view that the pRB-E2F3-EZH2 pathway may represent a key oncogenic axis that has an important role in determining development and aggressiveness of human prostate cancer ( Figure 5 ). EZH2 has been shown to represent an oncogene that can be activated by DNA amplification and/or overexpression, and whose overexpression is associated with poor clinical outcome (Varambally et al., 2002) , although contrary to this view Lapointe et al. (2004) have suggested that EZH2 may solely represent a marker of cell proliferation. In previous studies, we have presented evidence that E2F3 gene amplification and overexpression represent a fundamental mechanism in human bladder cancer development (Feber et al., 2004) . Here we show that, in prostate cancer, overexpression of E2F3 protein is an independent prognostic marker of poor clinical outcome. Supporting the role of E2F3 as an oncogene, its encoded protein has been demonstrated to have a critical role in controlling cell proliferation in both neoplastic and non-neoplastic cells (Leone et al., 1998; Humbert et al., 2000; Wu et al., 2001; Huang et al., 2003) . Mouse embryo fibroblasts in which the E2F3 gene has been knocked out (E2F3
) have a proliferation and cell cycle defect when compared to their wild-type counterparts. Inhibition of E2F3 activity by antibody microinjection impairs entry into S phase and in transgenic mouse studies E2F3 expression contributes to the ectopic proliferation of neuronal cells and lens fibre cells in Rb À/À null mice. Although there is no evidence for DNA amplification or increase in copy number of the E2F3 locus (6p22) in human prostate cancer (http://www.helsinki.fi/cmg/ cgh_data.html) the levels of nuclear staining of E2F3 in prostate cancers are similar to those observed in transitional cell carcinoma of the bladder. In human prostate cancer, overexpression of E2F3 therefore may occur by a mechanism that does not involve DNA amplification. Indeed it is well established that gene overexpression can occur by mechanisms other than DNA amplification as illustrated for human sarcomas where overexpression of the MDM2 gene can occur both in the presence and absence of DNA amplification (Cordon-Cardo et al., 1994) .
The importance of the pRB-E2F3-EZH2 control axis is further supported by data indicating that many different alterations found in prostate cancer may function through the common removal of pRB control at the G1/S transition in the cell cycle (Kibel and Isaacs, 2000) . It has been proposed that downregulation of pRB represents an early event in prostate cancer development and loss of pRB is a prognostic marker of cancer progression (Brooks et al., 1995; Theodorescu et al., 1997) . Loss of expression of p16, a CDK inhibitor and upstream regulator of pRB, is also of prognostic significance in locally advanced prostate cancer (Chakravarti et al., 2003) , with the downregulation of p16 expression probably resulting from gene hypermethylation or gene deletion (Konishi et al., 2002) . p14ARF, which like p16 is encoded by the INK4A/ARF locus, interacts with E2F3 promoting its degredation (Martelli et al., 2001) . Deletion or hypermethylation also represents a potential mechanism of removal of the p14ARF protein in a small proportion (16%) of prostate cancers For statistical analysis, the AJCC stage 4 tumours were divided into categories without (M0) or with (M1) distance metastases. Because only one patient had an AJCC stage 1 tumour, AJCC stage 2 tumours were used as a reference Transcription factor E2F3 overexpressed in prostate cancer CS Foster et al (Konishi et al., 2002) . Mutation and altered expression of other upstream regulators of pRB such as p53, p21 and MDM2 (Gao et al., 1995; Osman et al., 1999; Leite et al., 2001 ) have also been observed in prostate cancer, although mutations in the p53 gene are most frequently associated with metastatic and hormone-refractory disease (Heidenberg et al., 1995) .
It is particularly significant that prostate cancer exhibits both downregulation of pRB (Brooks et al., 1995; Theodorescu et al., 1997) and overexpression of E2F3. In bladder cancer, it appears that E2F3 overexpression and pRB inactivation can occur in the same tumours, and we have proposed that cooperation between these two events is required for bladder carcinogenesis (Feber et al., 2004) . This cooperation may be required because of the extremely high levels of the E2F inhibitor pRB commonly found in nonneoplastic cells. Thus, removal of functional pRB may be required for overexpression of E2F3 to exert its maximum effect. Our current data, presented herein, support the hypothesis that relative imbalance between declining expression of pRB and E2F3 overexpression is likely to be an important factor in regulating the genesis and/or progression of human prostate cancers.
Materials and methods
Prostate and control tissue
Prostate cancer specimens were obtained from a systematic series of patients who attended the Royal Marsden NHS Trust (RMNHST) uro-oncology clinic since 1992. The clinical database was searched for patients who had undergone TURP or radical prostatectomy. Paraffin wax blocks of prostatic tissue specimens were obtained from pathology archives at the referring hospitals and at the RMNHST. The earliest original diagnosis was in 1985. Prostatic tissues from men undergoing primary cystoprostatectomy for invasive transitional cell carcinoma of the urinary bladder were obtained from the tissue archives of the Department of Pathology and Molecular Genetics at the Royal Liverpool University Hospital (NHS) Trust and used as previously described as controls for the For statistical analysis, the AJCC stage 4 tumours were divided into categories without (M0) or with (M1) distance metastases. Because only one patient had an AJCC stage 1 tumour, AJCC stage 2 tumours were used as a reference Transcription factor E2F3 overexpressed in prostate cancer CS Foster et al immunohistochemical findings obtained with prostate cancer specimens (Cornford et al., 1999) .
Clinical staging and treatment
Patients were assessed by digital rectal examination, bone scan and CT scan of abdomen and pelvis or pelvic MRI scan where radical treatment was planned. The data for stage at diagnosis were held on the RMNHST research system. The stage was recorded using the UICC TNM system (Sobin and Wittekind, 1997) and for analysis was converted to the AJCC system (Greene et al., 2002) to provide an integrated clinical stage for each patient. As the AJCC group IV contained patients with either advanced locoregional disease or metastatic disease, for statistical analyses this group was subdivided into classes with or without distant metastases. Initial treatment for each patient was recorded as radical prostatecomy, radical radiotherapy, androgen deprivation alone or observation. PSA values were not used in our analyses because PSA of presentation data was only available for a small proportion of the cases. This study was approved by the Clinical Research and Ethics Committee at the Royal Marsden Hospital and Institute of Cancer Research. The analyses of the correlation of staining and clinical outcome was conducted as an audit of association of E2F3 expression with clinical outcome and the data were anonymised.
Antibodies
The murine monoclonal antibody to E2F3 was purchased from Upstate UK (Park Leys, Botolph Claydon, Buckinghamshire, Cat 05-551) and diluted 1 : 200 in Antibody Diluent (DakoCytomation, Ely, Cambridgeshire, Cat S2022) prior to use. Specificity of the Upstate antibody to detect E2F3 in immunohistochemical studies was established previously (Feber et al., 2004) . In Western analysis, the antibody detected only a protein doublet corresponding to the E2F3a and E2F3b protein isoforms. Immunohistochemically, the antibody demonstrated strong nuclear E2F3 staining only in cell lines that amplified and overexpressed E2F3 and did not identify a protein in cell lines that showed no E2F3 overexpression in Northern and Western blot studies.
Tissue microarrays
The TMA was composed of a total of 774 cores that represented normal epithelium (43 patients), hyperplastic epithelium (124 patients) and prostatic cancer (147 patients). All cores were then taken from tissue samples from men who were diagnosed with prostate cancer. The morphological criteria for selection of 'normal', 'hyperplastic' and 'malignant' prostatic epithelium conformed to previously published definitions (Foster, 2000; Foster et al., 2000) . 'Normal' epithelium comprised acinar and/or ductal epithelium in which the two cell layers of luminal and basal epithelium were clearly identified and within which no multilayering of either component was present. Furthermore, the cells were cytologically unremarkable with nuclei exhibiting a consistent pattern without enlargement or compaction. Intranuclear condensation of chromatin was a feature for exclusion. No nucleoli were visible. The term 'hyperplasia' defined those patterns in which there was increased and hence abnormal epithelial growth of either cytological or architectural type, but which did not contain features of dysplasia or malignancy. Such patterns included multilayering of cells within either the luminal or basal epithelial compartments. It is recognized that either type might be an isolated and independent finding, or could be associated with an adjacent region of atrophy, sclerosis or cystic glandular dilatation. None of these cases contained dysplastic appearances such as nuclear chromatin abnormalities or the presence of small or large nucleoli. 'Prostate cancer' was identified as malignant cells invading prostatic stromal connective tissues. Several patterns were identified according to conventional criteria (Foster and Sakr, 2001) . Appearances ranged from a well-differentiated acinar pattern to invasion by poorly differentiated single cells or sheets of malignant tissue. Examples of epithelial 'dysplasia' were not included in this tissue array because of the wide spectrum of morphological appearances that might be classified as 'dysplastic', and also because of the uncertain nature of the probable biological state (e.g. risk of progression to prostate cancer) of any particular lesion. Until appropriate criteria are available (similar to those recently defined for particular dysplastic lesions of the human breast) (Shaaban et al., 2002) , analysis of dysplastic prostatic lesions remains inappropriate in the current context. Similarly, non-invasive prostatic neoplasia, including high-grade PIN, in situ carcinoma and intra-epithelial Padgetoid spread were excluded from this study.
TMAs were constructed in 35 Â 22 Â 7 mm blocks of Lamb wax using a manual tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). Up to six cores of 0.6 mm diameter were taken from each tumour. For selected cases, up to eight cores were taken to check the consistency of immunohistochemical staining. Where possible, two cores were selected from microscopically normal tissue.
Immunohistochemistry
Sections were cut at 4 mm onto SuperfrostPlus glass slides (VWR International, Poole, Dorset, UK), dewaxed with xylene and rehydrated to water through graded ethanol rinses. Endogenous peroxidase activity was blocked by immersion of tissue sections in a 3% (w/v) solution of H 2 O 2 in methanol at room temperature for 12 min. Sections were rinsed in tap water Figure 5 Role of the pRB-E2F3-EZH2 control axis in determining aggressiveness in human prostate cancer. The INK4A/ARF gene encodes two proteins p16 and p14ARF that are negative regulators of the pRB-E2F3-EZH2 pathway. Genes overexpressed (red) or downregulated (green) in human prostate cancer are indicated. Red stripes indicate that overexpression of p53 measured in studies of clinical correlation was believed to represent underlying mutations in the p53 gene.
signifies that the indicated change in gene expression is associated with adverse clinical outcome (see Theodorescu et al., 1997; Varambally et al., 2002; Chakravarti et al., 2003) followed by deionized water. High-temperature antigen retrieval was then performed in a pressure-cooker, and comprised heating for 3 min at full pressure (103 kPa) in 10 mM EDTA buffer (pH 7.0). After rinsing in tap water followed by deionized water, sections were transferred to an Autostainer (DakoCytomation) for immunohistochemical staining. Sections were incubated with the primary antibody for 40 min at room temperature and washed with Tris-buffered saline (TBS, 0.05 M Tris, 0.12 M sodium chloride, 0.05% Tween 20, pH 7.6); the detection system was ChemMatet EnVisiont HRP (DakoCytomation, Cat K5007), used according to the manufacturer's instructions.
Analysis of E2F3 expression
Tissue cores were examined by the histopathologist blinded to each patient's identity and clinical features. Specimens were considered positive only when at least 5% of the contained epithelial cells (normal, hyperplastic or malignant) unequivocally expressed E2F3 staining. The 5% cutoff was chosen as the same criterion to distinguish positive and negative immunohistochemical staining as that used in our previous studies of bladder cancer (Feber et al., 2004) thus ensuring consistency of criteria between studies. E2F3 staining within nuclei was referred to as 'Type I'. For each tissue core, the percentage of nuclei within the epithelial component clearly staining positive was recorded. E2F3 staining within the cytoplasm occurring with a punctuate appearance ('Type II') was scored separately as positive or negative. Simultaneously with the analysis of E2F3 expression, each tissue core was scored as containing morphologically normal epithelium, epithelial hyperplasia or cancer. Data were entered into an electronic database by data managers also blinded to patient identity. Anonymised clinical data and histopathological data were then merged by the statistician.
Statistical analysis
Survival curves were generated using the methods of Kaplan and Meier (Kaplan and Meier, 1958) with the date of original diagnosis assigned as the base date. Overall survival analyses used death from any cause as the end point. Cause-specific survival analysis used death only from prostate cancer as the end point, patients dying from other causes being right censored at the time of death. Differences between groups were examined using the log-rank test. Univariate analyses were performed by Cox regression. Associations with categorical data were examined using the w 2 test and Fisher's exact test when expected cell counts were less than 5. Multivariate analyses of overall survival and cause-specific survival were also performed using stepwise Cox regression analysis (Cox and Oakes, 1984) according to the proportional hazards model to control for significant prognostic factors. The hazard ratios for the risk of death as (univariate and multivariate) were estimated from the Cox regression analyses. Factors included in the multivariate analysis were age, Gleason score, E2F3 staining status and AJCC stage. Where Gleason scores were not available, the grade of tumour was used to derive a Gleason score according to the following criteria: welldifferentiated tumours were scored 2.5, moderately differentiated tumours were scored 5.5 and poorly differentiated tumours were scored 8.5.
